There were number of times Todd was excited in the last few months and didnt result in PPS outcome. I wouldnt read too much into it. Now that we are way into the holidays, the chances of SEC approval on S1 NGIO is slim this month. I think we have to wait for Jan for NGIO listing which will move the PPS.

The other event which will have an impact on the PPS (IMO) is FDA IND resubmission.. I hope that should happen sooner as Generex should have peptide results which is required for submission.